GKOSGlaukos Corp
184.46USD-2.68%Mkt Cap: 11.18B $P/E:

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It off…

Key Statistics

Company
Market Cap11.18B $
Enterprise Value10.72B $
Revenue (TTM)612.84M $
Gross Profit282.76M $
Net Income (TTM)-187.69M $
Revenue/Share10.58 USD
Last Price184.46 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINUS3773221029
Valuation
P/E (Trailing)
P/E (Forward)366.61
PEG
EV/EBITDA-289.58
EV/Revenue17.50
P/S17.80
P/B15.95
EPS (TTM)-3.20
EPS (Forward)0.50
52W Range
73.1695% of range190.06
52W High190.06 USD
52W Low73.16 USD
Profitability
Gross Margin55.72%
Oper. Margin-8.49%
EBITDA Margin-6.04%
Profit Margin-36.99%
ROE-28.60%
ROA-21.01%
Growth
Revenue Growth49.50%
Earnings Growth
Cash Flow & Leverage
Operating CF-14.79M $
CapEx (TTM)24.27M $
FCF Margin2.52%
FCF Yield0.14%
Net Debt-178.62M $
Net Debt/EBITDA4.82
Balance Sheet
Debt/Equity0.16
Current Ratio5.04
Quick Ratio4.16
Book Value/Sh11.60 USD
Cash/Share4.855 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)197.15 USD
Upside (mean)+6.9%
Target Range172.00 USD225.00 USD
$172.00+6.9% to mean$225.00
# Analysts13
Ownership
Shares Out.58.98M
Float56.81M
Insiders3.60%
Institutions105.45%
Short Interest
Short Ratio4.1d
Short % Float7.45%
Short % Out.6.15%
Shares Short3.63M
Short (prev mo.)4.45M
Technical
SMA 50155.62 (+18.5%)
SMA 200124.22 (+48.5%)
Beta0.76
S&P 52W Chg18.16%
Avg Vol (30d)696.73K
Avg Vol (10d)705.54K
Technical Indicators
RSI (14)77.3
MACD10.3387
MACD Signal9.4053
MACD Hist.+0.9334
BB Upper198.16 USD
BB Middle171.06 USD
BB Lower143.96 USD
BB Width31.68%
ATR (14)6.416 USD
Vol Ratio (20d)0.50x